Marks Group Wealth Management Inc Grows Stock Position in argenx SE (NASDAQ:ARGX)

Marks Group Wealth Management Inc boosted its holdings in argenx SE (NASDAQ:ARGX) by 11.7% during the fourth quarter, HoldingsChannel reports. The fund owned 1,316 shares of the company’s stock after buying an additional 138 shares during the period. Marks Group Wealth Management Inc’s holdings in argenx were worth $809,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its position in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares during the last quarter. Choreo LLC boosted its position in shares of argenx by 4.4% during the 4th quarter. Choreo LLC now owns 551 shares of the company’s stock worth $342,000 after purchasing an additional 23 shares during the period. Raymond James Trust N.A. increased its holdings in argenx by 6.0% in the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after purchasing an additional 28 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock valued at $286,000 after purchasing an additional 43 shares during the last quarter. Finally, Aaron Wealth Advisors LLC raised its position in argenx by 10.1% in the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $301,000 after purchasing an additional 45 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Stock Performance

NASDAQ ARGX opened at $649.09 on Thursday. argenx SE has a one year low of $349.86 and a one year high of $678.21. The firm has a market cap of $39.44 billion, a PE ratio of -737.60 and a beta of 0.58. The firm’s fifty day moving average is $638.76 and its two-hundred day moving average is $580.34.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a research report on Tuesday, November 12th. Truist Financial reiterated a “buy” rating and issued a $700.00 price objective (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Finally, Citigroup boosted their price objective on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.